| 摘要: |
| ［摘要］ 目的 探讨体外受精-胚胎移植（IVF-ET）中GnRH拮抗剂治疗多囊卵巢综合征（PCOS）对患者卵泡液中白细胞介素-1β（IL-1β）的影响及与助孕结局的关系。方法 选择2011-08～2012-09在该院生殖医疗中心行IVF-ET的PCOS不孕患者76例，随机分为A组（GnRH拮抗剂组）28例（研究组），B组（GnRH激动剂长方案组）48例（对照组），比较分析两组患者的卵泡液中IL-1β水平及其与助孕结局的关系。结果 两组卵泡液中IL-1β浓度比较差异无统计学意义（P>0.05）；子宫内膜厚度、获卵数、成熟卵率、受精率、卵裂率、优胚率、种植率、临床妊娠率方面，两组比较差异无统计学意义（P>0.05）；A组的Gn总用量、Gn用药天数明显比B组少（P<0.01）；A组绒毛膜促性腺激素（HCG）日E2水平低于B组（P<0.05）；两组的卵巢过度刺激综合征（OHSS）发生率差异无统计学意义（P>0.05）；A组的周期取消率明显低于B组（P<0.01）。结论 IVF-ET中GnRH拮抗剂治疗PCOS不会改变卵泡液中的IL-1β水平，不影响卵泡的发育、卵母细胞的成熟、受精、卵裂能力及胚胎的着床，故GnRH拮抗剂方案是安全有效的。 |
| 关键词: GnRH拮抗剂 多囊卵巢综合征 体外受精-胚胎移植 白细胞介素-1β |
| DOI：10.3969/j.issn.1674-3806.2013.08.05 |
| 分类号:R 71 |
| 基金项目:南宁市科技攻关与新产品试制项目课题（编号：201106045C）；广西卫生厅科研课题（编号：Z2011152） |
|
| Study on relationship between levels of IL-1β in follicular fluid and IVF-ET outcome in PCOS patients |
|
HUANG Ying, QIU Ying, TAN Xiu-qun
|
|
Reproductive Medical Center of the Third Affiliated Hospital of Guangxi Medical University, Nanning 530031, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the effect of GnRH antagonist in IVF-ET on IL-1β in follicular fluid and the relationship between GnRH antagonist and IVF-ET outcome in polycystic ovarian syndrome(PCOS) patients.Methods Seventy-six cases of PCOS patients undergoing IVF-ET between August 2011 and September 2012 were divided randomly into two groups: Group A(study group): 28 patients with PCOS were subjected to a protocol of gonadotropin-releasing hormone antagonist. Group B(control group): 48 patients with PCOS were subjected to a long protocol of gonadotropin-releasing hormone agonist. The level of IL-β of the two groups and the relationships between GnRH antagonist and IVF-ET outcome were analyzed.Results The two groups were similar with respect to IL-1β in follicular fluid(P>0.05); the two groups were similar with respect to endometrium thickness, the number of oocyte, the mature rate of the oocytes, fertilization rates, cleavage rates, the rate of the high-quality embryos, implantation rate, pregnancy rate(P>0.05). The doses of gonadotropin and the days of administration in Group A was less than those in Group B(P<0.01). The levels of serum E2 on day of HCG administration, and the cycle cancellation rate in Group A was lower than that in Group B(P<0.05 or 0.01). The difference of the incidence rate of OHSS was not significant(P>0.05) between the two groups.Conclusion It is demonstrated that GnRH antagonist in PCOS patients undergoing IVF-ET did not alter levels of IL-1β in follicular fluid, the development of follicle and the oocyte competence. These results demonstrated the high-performance and safety of this drug on controlled ovarian stimulation protocol. |
| Key words: GnRH antagonist Polycystic ovarian syndrome(PCOS) IVF-ET IL-1β |
